Abstract
Selective vectorization of Cisplatin (CisPt) to Glioblastoma U87 cells was exploited by the fabrication of a hybrid nanocarrier composed of magnetic γ-Fe2O3 nanoparticles and nanographene oxide (NGO). The magnetic component, obtained by annealing magnetite Fe3O4 and characterized by XRD measurements, was combined with NGO sheets prepared via a modified Hummer’s method. The morphological and thermogravimetric analysis proved the effective binding of γ-Fe2O3 nanoparticles onto NGO layers. The magnetization measured under magnetic fields up to 7 Tesla at room temperature revealed superparamagnetic-like behavior with a maximum value of MS = 15 emu/g and coercivity HC ≈ 0 Oe within experimental error. The nanohybrid was found to possess high affinity towards CisPt, and a rather slow fractional release profile of 80% after 250 h. Negligible toxicity was observed for empty nanoparticles, while the retainment of CisPt anticancer activity upon loading into the carrier was observed, together with the possibility to spatially control the drug delivery at a target site.
Highlights
Malignant glioma is one of the most aggressive brain tumors, and the major cause of death from central nervous system cancers [1,2,3,4,5]
The therapeutic efficiency of chemotherapy is remains unsatisfactory for two main reasons: (i) the rare brain penetration of the anticancer agents systemically administered through the blood brain barrier (BBB) [9], and (ii) the poor glioma targeting of employed chemotherapeutics [10]
In the present study we explored the possibility to employ nanographene oxide (NGO)–Iron oxide nanohybrids (γ-Fe2O3@NGO) as a CisPt carrier for glioblastoma treatment by intercalating γ-Fe2O3 nanoparticles into NGO sheets
Summary
Malignant glioma is one of the most aggressive brain tumors, and the major cause of death from central nervous system cancers (median survival times less than 15 months from diagnosis) [1,2,3,4,5]. The therapeutic efficiency of chemotherapy is remains unsatisfactory for two main reasons: (i) the rare brain penetration of the anticancer agents systemically administered through the blood brain barrier (BBB) [9], and (ii) the poor glioma targeting of employed chemotherapeutics [10]. The latter issue is the main obstacle in the clinical treatment of Glioma with cis-diamminedichloroplatinum(II) (CisPt) [11], one of the most effective anticancer agents. Chemical, and morphological properties, CisPt was loaded onto the nanocarrier for several drug-to-carrier ratios and their cytotoxicity was tested on human U87 cell lines
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
